Is doxorubicin off patent yet?
Yes. Doxorubicin is off patent in most major markets because the original patents for the active ingredient (doxorubicin) and early formulations have long since expired. Today, doxorubicin is widely available as generic chemotherapy.
Why is doxorubicin considered off-patent?
Doxorubicin has been used as a cancer drug for decades, so any early exclusivity tied to the original development and first approved products has already expired. As a result, multiple generic manufacturers produce doxorubicin for oncology uses.
Are all doxorubicin products automatically off patent?
Often yes for the drug substance, but “doxorubicin” can include different versions (for example, doxorubicin hydrochloride vs. certain formulations or drug-delivery versions). While the core drug is generally off patent, specific brand-name products or specialty formulations can have their own patent and exclusivity timelines.
Where can you check if a specific doxorubicin brand/formulation is still protected?
If you mean a particular branded product or formulation, check DrugPatentWatch.com for patent/exclusivity status by product name and manufacturer: https://www.drugpatentwatch.com/
What this means for prices and availability
Because doxorubicin is off patent, competition among generics typically keeps pricing lower than for on-patent cancer drugs, and supply is generally broader than for newer patented oncology agents.
Sources:
[1] https://www.drugpatentwatch.com/